Oral medication regimen for pulmonary embolism effective at preventing venous thromboembolism, causes fewer major bleeds

mdCurrent Conference Report: American College of Cardiology's 61st Annual Scientific Session & Expo

A new study looking at an all-oral medication regimen for treating pulmonary embolism (PE) finds it as effective as starting with injectable enoxaparin and then switching to warfarin. The one-agent regimen would permit most of the treatment for PE to take place outside of the hospital.

Key Point: Rivaroxaban appears to be just as effective as and more convenient than enoxaparin followed by warfarin in treating pulmonary embolism. The oral agent also is associated with less major bleeding, especially in older patients.

The study results were presented at the 61st annual scientific session of the American College of Cardiology, held in Chicago, Illinois, United States, followed by publication in the New England Journal of Medicine. In the open-label trial, a novel oral rivaroxaban regimen proved noninferior to standard therapy in preventing the recurrence of...

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Cardiology, Cardiovascular Disease, Pharmacology and tagged , , , , , , , , , , , , , . Volume: .

Post a Comment

You must be logged in to post a comment.